Free Trial
NASDAQ:ATHA

Athira Pharma (ATHA) Stock Price, News & Analysis

$2.54
+0.02 (+0.79%)
(As of 05/21/2024 ET)
Today's Range
$2.46
$2.58
50-Day Range
$1.92
$2.74
52-Week Range
$1.33
$4.30
Volume
55,981 shs
Average Volume
343,452 shs
Market Capitalization
$97.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Athira Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
648.0% Upside
$19.00 Price Target
Short Interest
Healthy
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of Athira Pharma in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.80) to ($3.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

539th out of 920 stocks

Biological Products, Except Diagnostic Industry

75th out of 150 stocks

ATHA stock logo

About Athira Pharma Stock (NASDAQ:ATHA)

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

ATHA Stock Price History

ATHA Stock News Headlines

ATHA Athira Pharma, Inc.
Athira Pharma Appoints Javier San Martin As New Chief Medical Officer
Athira Pharma, Inc. (ATHA)
See More Headlines
Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
5/21/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ATHA
Fax
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$19.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+648.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-117,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
30,740,000
Market Cap
$97.36 million
Optionable
Optionable
Beta
2.83
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

ATHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Athira Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHA shares.
View ATHA analyst ratings
or view top-rated stocks.

What is Athira Pharma's stock price target for 2024?

1 equities research analysts have issued 12 month price targets for Athira Pharma's shares. Their ATHA share price targets range from $19.00 to $19.00. On average, they anticipate the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 648.0% from the stock's current price.
View analysts price targets for ATHA
or view top-rated stocks among Wall Street analysts.

How have ATHA shares performed in 2024?

Athira Pharma's stock was trading at $2.43 at the beginning of 2024. Since then, ATHA shares have increased by 4.5% and is now trading at $2.54.
View the best growth stocks for 2024 here
.

When is Athira Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our ATHA earnings forecast
.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.11.

What ETF holds Athira Pharma's stock?

Simplify Propel Opportunities ETF holds 1,492,792 shares of ATHA stock, representing 4.10% of its portfolio.

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

Athira Pharma (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.

Who are Athira Pharma's major shareholders?

Athira Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.26%), BML Capital Management LLC (2.35%), Acadian Asset Management LLC (1.43%), Jacobs Levy Equity Management Inc. (1.30%), GSA Capital Partners LLP (0.46%) and Mirador Capital Partners LP (0.05%). Insiders that own company stock include Andrew Gengos, Glenna Mileson, Hans Moebius, James A Johnson, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington.
View institutional ownership trends
.

How do I buy shares of Athira Pharma?

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATHA) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners